Leukemia Research
Volume 28, Issue 10 , Pages 1097-1105 , October 2004

Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide: III. Action on human megakaryocytopoiesis: focus on essential thrombocythemia

  • Rita Fazzi

      Affiliations

    • Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
    • ,
  • Sara Galimberti

      Affiliations

    • Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
    • ,
  • Simone Pacini

      Affiliations

    • Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
    • ,
  • Rossana Testi

      Affiliations

    • Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
    • ,
  • Antonio Azzarà

      Affiliations

    • Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
    • ,
  • Enrico Orciuolo

      Affiliations

    • Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
    • ,
  • Luisa Trombi

      Affiliations

    • Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
    • ,
  • Maria Rita Metelli

      Affiliations

    • Department of Experimental Pathology, Medical Biotechnologies, Infectious Diseases and Epidemiology, University of Pisa, Pisa, Italy
    • ,
  • Mario Petrini

      Affiliations

    • Department of Oncology, Transplants and Advanced Technologies in Medicine, Hematology Division, University of Pisa, Ospedale S. Chiara, Via Roma 67, Pisa 56100, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-050-992815; fax: +39-050-830162.

Received 1 September 2003 ,Accepted 2 January 2004.

References 

  1. Harrison CN, Gale RE, Machin SJ, et al.  A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood. 1999;93:417–424
  2. Li Y, Hetet G, Maurer AM, et al.  Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF. Br. J. Haematol. 1994;87:471–476
  3. Li Y, Hetet G, Kiladjian JJ, et al.  Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br. J. Haematol. 1996;92:60–66
  4. Taksin AL, Couedic JP, Dusanter-Fourt I, et al.  Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L. Blood. 1999;93:125–139
  5. Li J, Xia Y, Kuter DJ. The platelet thrombopoietin receptor number and function are markedly decreased in patients with essential thrombocythaemia. Br. J. Haematol. 2000;111:943–953
  6. Westwood NB, Pearson TC. Diagnostic applications of haemopoietic progenitor culture techniques in polycythaemias and thrombocythaemias. Leuk. Lymphoma. 1996;22(Suppl. 1):95–103
  7. Zweegman S, Veenhof MA, Huijgens PC, et al.  Regulation of megakaryocytopoiesis in an in vitro stroma model: preferential adhesion of megakaryocytic progenitors and subsequent inhibition of maturation. Exp. Hematol. 2000;28:401–410
  8. Gurevitch O, Slavin S, Muhlrad A, et al.  Osteogenic growth peptide increases blood and bone marrow cellularity and enhances engraftment of bone marrow transplants in mice. Blood. 1996;88:4719–4724
  9. Fazzi R, Testi R, Trasciatti S, et al.  Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk. Res. 2002;26:19–27
  10. Fazzi R, Galimberti S, Testi R, et al.  Bone and bone marrow interactions: hematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. II. Action on human hematopoietic stem cells. Leuk. Res. 2002;26:839–848
  11. Fazzi R, Pacini S, Testi R, et al.  Carboxy-terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis. Br. J. Haematol. 2003;121:76–85
  12. Chen YC, Bab I, Mansur N, et al.  Structure-bioactivity of C-terminal pentapeptide of osteogenic growth peptide [OGP(10–14)]. J. Pept. Res. 2000;56:147–156
  13. Murphy S, Iland H, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin. Hematol. 1986;23:177
  14. Hogge D, Fanning S, Bockhold K, et al.  Quantitation and characterization of human megakaryocyte colony-forming cells using a standardized serum-free agarose assay. Br. J. Haematol. 1997;96:790–800
  15. Petrini M, Caracciolo F, Carulli G, et al.  Vitamin D3 administration and multidrug resistance in acute nonlymphoblastic leukemia. Acta Haematol. 1993;89:184–188
  16. Drexler HG, Quentmeier H. Cytokine response profiles of human myeloid factor-dependent leukemia cell lines. Leukemia. 1997;11:701–708
  17. Testi R, Mattii L, Di Simone D, et al.  Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines. Leuk. Res. 1995;19:257–261
  18. Junker U, Haufe CC, Nuske K, et al.  Elevated plasma TGF-beta1 in renal diseases: cause or consequence?. Cytokine. 2000;12:1084–1091
  19. Hart CE, Bailey M, Curtis DA, et al.  Purification of PDGF-AB and PDGF-BB from human platelet extracts and identification of all three PDGF dimers in human platelets. Biochemistry. 1990;29:166–172
  20. Bailly S, Fay M, Ferrua B, et al.  Comparative production of IL-1 beta and IL-1 alpha by LPS-stimulated human monocytes: ELISAs measurement revisited. Cytokine. 1994;6:111–115
  21. Aukrust P, Liabakk NB, Muller F, et al.  Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection—correlations to clinical, immunologic, and virologic parameters. J. Infect. Dis. 1994;169:420–424
  22. Di Simone D, Testi R, Caracciolo F, et al.  Glutathione-S-transferase activity and multidrug resistance phenotype in chronic lymphocytic leukemia: do they have any clinical relevance?. Haematologica. 1995;80:103–107
  23. Bab I, Gazit D, Muhlrad A, et al.  Regenerating bone marrow produces a potent growth-promoting activity to osteogenic cells. Endocrinology. 1988;123:345–352
  24. Bab I, Gazit D, Chorev M, et al.  Histone H4-related osteogenic growth peptide (OGP): a novel circulating stimulator of osteoblastic activity. EMBO J. 1992;11:1867–1873
  25. Bab I, Gavish H, Namdar-Attar M, et al.  Isolation of mitogenically active C-terminal truncated pentapeptide of osteogenic growth peptide from human plasma and culture medium of murine osteoblastic cells. J. Pept. Res. 1999;54:408–414
  26. Axelrad AA, Eskinazi D, Correa PN, et al.  Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 2000;96:3310–3321
  27. Fortunel NO, Hatzfeld A JA. Transforming growth factor-beta: pleiotropic role in the regulation of hematopoiesis. Blood. 2000;96:2022–2036
  28. Kalina U, Koschmieder S, Hofmann WK, et al.  Transforming growth factor-beta1 interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells. Exp. Hematol. 2001;29:602–608
  29. Sakamaki S, Hirayama Y, Matsunaga T, et al.  Transforming growth factor-beta1 (TGF-beta1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-beta receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-beta itself with high specificity. Blood. 1999;94:1961–1970

PII: S0145-2126(04)00064-5

doi: 10.1016/j.leukres.2004.01.019

Leukemia Research
Volume 28, Issue 10 , Pages 1097-1105 , October 2004

Article Tools

* Image Usage & Resolution